GO:0019862 IgA binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019862 (IgA binding) is a molecular function defined as binding to an immunoglobulin of the IgA isotype, encompassing interactions with both IgA1 and IgA2 and their monomeric, dimeric, and secretory forms.
• The best-characterized IgA receptors are FcαRI (CD89) on myeloid cells, pIgR/SC that mediates epithelial transcytosis, and the Fcα/μ receptor, each engaging distinct IgA domains.
• IgA binding is central to mucosal immunity, shaping the gut microbiota through immune exclusion and coating of commensal and pathogenic bacteria.
• Dysregulated IgA binding contributes to IgA nephropathy, where decreased IgA binding and altered glycosylation are observed, and to allergic disease through allergen-specific IgA responses.
• Therapeutic blockade of IgA binding is an emerging strategy in autoimmune nephropathy, as illustrated by telitacicept targeting BAFF/APRIL to reduce IgA production.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of IgA receptor genes and IgA-binding proteins in human cell lines and organoids.
Description
GO:0019862 (IgA binding) is a molecular function term in the Gene Ontology that describes the selective non-covalent interaction of a protein or other molecule with an immunoglobulin of the IgA isotype. IgA is the most abundant antibody at mucosal surfaces and exists as monomeric IgA in serum and dimeric or secretory IgA (SIgA) in secretions, where it performs immune exclusion and shapes host-microbiota interactions. The functional consequences of IgA binding depend on the receptor involved: FcαRI (CD89) triggers phagocytosis and inflammatory signaling on myeloid cells, while the polymeric immunoglobulin receptor (pIgR) mediates transcytosis of dimeric IgA across epithelia. Because IgA binding bridges adaptive humoral immunity and innate effector cells, it is a focal point for understanding mucosal defense, autoimmune nephropathy, and allergic disease. Researchers studying IgA binding need robust models to interrogate receptor-ligand specificity, glycosylation-dependent affinity, and downstream signaling, making this GO term a practical entry point for CRISPR-based functional genomics.
IgA binding At A Glance
| GO ID | GO:0019862 |
|---|---|
| GO term | IgA binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to an immunoglobulin of an IgA isotype. |
| Major function | Selective recognition of IgA antibodies by receptors and IgA-binding proteins, enabling immune exclusion, transcytosis, and effector cell activation. |
| Representative receptors | FcαRI (CD89), pIgR/secretory component, Fcα/μ receptor. |
| IgA isotypes | IgA1 and IgA2, in monomeric, dimeric, and secretory forms. |
| Disease relevance | IgA nephropathy, allergic disease, inflammatory bowel disease, autoimmune nephropathy. |
What Is GO:0019862?
In our own words, GO:0019862 (IgA binding) is the molecular function of selectively and non-covalently interacting with an immunoglobulin of the IgA isotype. This includes binding to IgA1, IgA2, monomeric IgA, dimeric IgA, and secretory IgA, and it is mediated by dedicated IgA receptors or IgA-binding proteins of host or microbial origin.
Why Is IgA binding Important in Cell Biology?
IgA binding is important because it determines how the most abundant mucosal antibody engages host receptors and microbes, thereby controlling immune exclusion, epithelial transport, and inflammatory output. Perturbations in IgA binding are directly implicated in IgA nephropathy, where decreased IgA binding levels accompany increased IgG sialylation, and in allergic disease, where allergen-specific IgA contributes to immune regulation. Therapeutically, modulating IgA production and binding is being explored in autoimmune nephropathy with agents such as telitacicept, and IgA coating of gut bacteria is a key mechanism in inflammatory bowel disease and microbiome homeostasis.
• Defines the first step of IgA-mediated immune exclusion at mucosal surfaces.
• Enables pIgR-dependent transcytosis of dimeric IgA into secretions.
• Triggers FcαRI-mediated phagocytosis, degranulation, and cytokine release on myeloid cells.
• Shapes the composition of the gut microbiota through IgA coating of commensal and pathogenic strains.
• Contributes to IgA nephropathy pathogenesis via altered IgA binding and glycosylation.
• Modulates allergic inflammation through allergen-specific IgA responses.
• Provides a target for therapeutic blockade in autoimmune nephropathy.
• Serves as a model for studying glycosylation-dependent protein-protein interactions.
• Links adaptive humoral immunity to innate effector functions.
• Offers a tractable readout for CRISPR screens of receptor and glycan genes.
Molecular Mechanism of IgA binding
IgA isotypes and molecular forms
In simple terms: IgA comes in two flavors (IgA1 and IgA2) and several shapes (monomer, dimer, secretory), and each shape can bind receptors differently.
IgA binding is not a single interaction but a family of interactions defined by the IgA isotype and its quaternary structure. Human IgA1 and IgA2 differ in hinge-region length and glycosylation, and IgA can exist as monomers, dimers, or secretory IgA (SIgA) complexed with the secretory component. These structural differences influence which receptors are engaged and with what affinity, and they are central to the functional diversity of IgA binding in serum and mucosa.
FcαRI (CD89) recognition of IgA
In simple terms: FcαRI is the main IgA receptor on immune cells, and it grabs the Fc part of IgA to trigger killing and inflammation.
FcαRI (CD89) is a myeloid-cell receptor that binds the Fc region of both IgA1 and IgA2, initiating signaling through the FcR γ-chain and leading to phagocytosis, respiratory burst, and cytokine release. The IgA-FcαRI interaction is a prototype for IgA binding and has been structurally and functionally characterized, including its blockade by streptococcal IgA-binding proteins. This receptor is a key effector arm of IgA-mediated immunity and a target for anti-inflammatory intervention.
pIgR and secretory component-mediated transcytosis
In simple terms: pIgR carries dimeric IgA across epithelial cells and then becomes part of secretory IgA.
The polymeric immunoglobulin receptor (pIgR) binds dimeric IgA at the basolateral surface of epithelial cells and transcytoses it to the apical surface, where proteolytic cleavage releases secretory IgA containing the secretory component. This pathway is essential for delivering IgA into mucosal secretions and for immune exclusion. Functional studies with IgM and IgA immunoglobulins have dissected pIgR binding and downstream complement-dependent cytotoxicity activities.
Fcα/μ receptor and additional IgA-binding proteins
In simple terms: Other receptors and microbial proteins also bind IgA, broadening the functional repertoire.
The Fcα/μ receptor binds both IgA and IgM and contributes to antigen uptake and presentation. In addition, pathogenic bacteria express IgA-binding proteins that block FcαRI engagement as an immune evasion strategy, illustrating the evolutionary pressure on IgA binding interfaces. These alternative binders expand the biological contexts in which GO:0019862 operates, from host defense to microbial pathogenesis.
Glycosylation and affinity regulation
In simple terms: Sugar chains on IgA change how tightly it binds receptors, which matters in disease.
IgA glycosylation, particularly O-glycosylation of the IgA1 hinge region, modulates receptor binding and immune complex formation. In IgA nephropathy, decreased IgA binding levels are accompanied by increased IgG sialylation, indicating that glycan remodeling can alter IgA-receptor interactions. This regulatory layer makes IgA binding sensitive to the cellular glycosylation machinery and a target for therapeutic glyco-engineering.
Microbial IgA coating and immune exclusion
In simple terms: IgA sticks to gut bacteria, tagging them for containment or removal.
Metagenomic immunoglobulin sequencing has revealed that IgA coats specific microbial strains in the healthy human gut, and mouse IgA can modulate human gut microbiota in inflammatory bowel disease patients. This coating is a direct consequence of IgA binding to bacterial surface antigens and is a major mechanism of immune exclusion and microbiota shaping. It also provides a functional readout for studying IgA binding in complex microbial communities.
Key Genes Involved in GO:0019862 IgA binding
The following genes encode the principal receptors, adaptors, and glycosylation enzymes that mediate or regulate IgA binding in human cells.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FCAR | Encodes FcαRI (CD89), the myeloid IgA Fc receptor | Central to IgA-mediated phagocytosis and inflammatory signaling |
| PIGR | Encodes the polymeric immunoglobulin receptor | Mediates epithelial transcytosis of dimeric IgA and secretory component release |
| FCAMR | Encodes the Fcα/μ receptor | Binds IgA and IgM and contributes to antigen uptake |
| FCGRT | Encodes the neonatal Fc receptor FcRn | Modulates IgA half-life and transport, indirectly affecting IgA binding |
| C1GALT1 | Encodes core 1 β3-galactosyltransferase | Controls IgA1 O-glycosylation and receptor affinity |
| C1GALT1C1 | Encodes the chaperone COSMC for C1GALT1 | Regulates IgA1 glycosylation and IgA nephropathy risk |
| ST6GALNAC2 | Encodes a sialyltransferase | Modifies IgA1 hinge glycans and binding properties |
| B4GALT1 | Encodes β1,4-galactosyltransferase | Contributes to IgA glycosylation and immune complex formation |
| JCHAIN | Encodes the joining chain of dimeric IgA | Required for dimeric IgA assembly and pIgR binding |
| IGHA1 | Encodes IgA1 heavy chain | Defines IgA1 isotype specificity and glycosylation sites |
| IGHA2 | Encodes IgA2 heavy chain | Defines IgA2 isotype specificity and receptor engagement |
| TNFSF13 | Encodes APRIL, a cytokine promoting IgA class switching | Therapeutic target in IgA-mediated autoimmunity |
| TNFSF13B | Encodes BAFF, a cytokine promoting IgA production | Targeted by telitacicept in autoimmune nephropathy |
| TNFRSF13B | Encodes TACI, a receptor for BAFF/APRIL | Regulates IgA class switching and plasma cell survival |
| TNFRSF13C | Encodes BAFF-R | Modulates B-cell survival and IgA responses |
| AICDA | Encodes activation-induced cytidine deaminase | Required for IgA class switch recombination |
| CD79A | Encodes the B-cell receptor signaling subunit | Supports IgA B-cell activation and differentiation |
How Is IgA binding Regulated?
IgA binding is regulated at multiple levels. Cytokines BAFF (TNFSF13B) and APRIL (TNFSF13) control IgA class switching and plasma cell survival, and their blockade by telitacicept reduces IgA production in autoimmune nephropathy. Glycosylation of IgA1, governed by enzymes such as C1GALT1 and its chaperone COSMC, modulates receptor affinity and immune complex formation, and altered glycosylation is linked to decreased IgA binding in IgA nephropathy. Receptor expression levels, including FcαRI on myeloid cells and pIgR on epithelia, further tune IgA binding capacity, and microbial IgA-binding proteins can competitively block these interactions. Together, these layers provide multiple entry points for experimental perturbation.
IgA binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FCAR | IgA-mediated inflammation and autoimmune nephropathy | Fcar knockout myeloid cell lines and mouse models |
| PIGR | Mucosal immune exclusion and IgA nephropathy | PIGR knockout epithelial organoids and transcytosis assays |
| C1GALT1 | IgA nephropathy and glycosylation defects | C1GALT1 point-mutation knock-in cell lines |
| TNFSF13B | Autoimmune nephropathy and IgA class switching | BAFF overexpression and telitacicept-treated B-cell models |
| JCHAIN | Dimeric IgA assembly and pIgR binding | JCHAIN knockout plasma cell lines |
IgA nephropathy and autoimmune nephropathy
IgA nephropathy is characterized by deposition of IgA-containing immune complexes in the glomerulus, and decreased IgA binding levels have been observed alongside increased IgG sialylation in patients. This suggests that altered IgA-receptor interactions and glycosylation contribute to disease pathogenesis. Therapeutic strategies that reduce IgA production, such as telitacicept targeting BAFF and APRIL, are being evaluated in autoimmune nephropathy, highlighting the clinical relevance of IgA binding pathways.
Allergic disease
Allergen-specific IgA, along with IgE and IgG, plays a role in allergic disease, where IgA binding to allergens and receptors can modulate inflammatory responses. Understanding how IgA binding contributes to immune regulation versus pathology is important for designing allergen-specific immunotherapies and for interpreting mucosal immune signatures in allergic patients.
Inflammatory bowel disease and microbiome
IgA coating of gut bacteria is a key mechanism of host-microbiota mutualism, and metagenomic immunoglobulin sequencing has revealed strain-specific IgA coating in the healthy human gut. In inflammatory bowel disease, mouse IgA can modulate human gut microbiota, indicating that IgA binding directly influences microbial composition and intestinal inflammation. These findings position IgA binding as a therapeutic and diagnostic axis in IBD.
From IgA binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FCAR abolish IgA-mediated phagocytosis? | FCAR knockout in myeloid cell lines (e.g., THP-1) |
| Does a specific PIGR point mutation impair IgA transcytosis? | PIGR point-mutation knock-in epithelial cells |
| Can tagged FcαRI track IgA binding dynamics? | Tagged knock-in of FCAR in primary-like macrophages |
| Does C1GALT1 overexpression alter IgA1 glycosylation and binding? | C1GALT1 overexpression in IgA-producing cell lines |
| Which genes regulate IgA coating of gut bacteria? | CRISPR library screening in epithelial-microbiota co-culture |
| Does BAFF/APRIL blockade reduce IgA binding in autoimmunity? | TNFSF13B/TNFSF13 knockout B-cell models |
How to Study the IgA binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics of IgA-receptor interactions | Characterizing FcαRI and pIgR binding |
| Flow cytometry | Cell surface IgA binding and receptor expression | Myeloid cell and bacterial IgA coating assays |
| IgA-SEQ | Microbial strains coated by IgA | Gut microbiome and IBD studies |
| Mass spectrometry glycomics | IgA1 O-glycosylation and IgG sialylation | IgA nephropathy biomarker studies |
| ELISA | IgA binding levels in serum or secretions | Clinical and experimental quantification |
| Transcytosis assays | pIgR-mediated IgA transport | Epithelial barrier studies |
| Phagocytosis assays | FcαRI-mediated uptake | Myeloid effector function studies |
| CRISPR screening | Genes regulating IgA binding | Functional genomics of IgA receptors |
Surface plasmon resonance and affinity measurements
Surface plasmon resonance (SPR) and related biosensor methods measure the affinity and kinetics of IgA binding to immobilized receptors such as FcαRI or pIgR. These biophysical assays are essential for quantifying how glycosylation or point mutations alter binding constants and for validating receptor-ligand specificity.
Flow cytometry and IgA coating assays
Flow cytometry using fluorescently labeled IgA or anti-IgA antibodies detects IgA binding to cell surfaces and to microbial strains, enabling quantification of receptor expression and IgA coating. This approach is widely used to study FcαRI-mediated binding on myeloid cells and IgA coating of gut bacteria.
Metagenomic immunoglobulin sequencing (IgA-SEQ)
IgA-SEQ combines IgA pulldown with metagenomic sequencing to identify which microbial strains are coated by IgA in complex communities. This method has revealed strain-specific IgA coating in the healthy human gut and is applicable to IBD and other microbiome studies.
Glycosylation analysis by mass spectrometry
Mass spectrometry-based glycomics and glycoproteomics characterize IgA1 O-glycosylation and IgG sialylation, which regulate IgA binding and immune complex formation. These methods are critical for linking glycan changes to functional alterations in IgA-receptor interactions in disease.
How CRISPR Can Be Used to Study GO:0019862 IgA binding
Knockout
CRISPR knockout of FCAR, PIGR, or FCAMR in human cell lines abolishes specific IgA binding activities, providing causal evidence for receptor function. Knockout models are also used to test whether loss of glycosylation enzymes such as C1GALT1 alters IgA1 binding and immune complex formation.
Point Mutation
Point-mutation knock-in of residues in the IgA-binding interface of FcαRI or pIgR allows precise mapping of affinity determinants and glycosylation-dependent interactions. These models are valuable for dissecting how disease-associated variants affect IgA binding without confounding expression changes.
Knock-in
Tagged knock-in of FCAR or PIGR with fluorescent or epitope tags enables real-time tracking of IgA binding, internalization, and transcytosis in live cells. Knock-in of human IgA1 or IgA2 into mouse models can humanize IgA binding for translational studies.
Overexpression
Overexpression of IgA receptors or IgA heavy chains in cell lines increases IgA binding capacity and can model disease-associated gain-of-function states. Overexpression of BAFF or APRIL (TNFSF13B/TNFSF13) drives IgA class switching and is used to study autoimmune nephropathy mechanisms.
How EDITGENE Supports IgA binding Research
Researchers studying IgA binding-related genes often need to determine whether a candidate gene is causally involved in receptor-ligand recognition, glycosylation-dependent affinity, or downstream effector signaling. EDITGENE provides end-to-end CRISPR cell model generation and screening services tailored to GO:0019862 and related mucosal immunology targets.
Contact EDITGENE today to design your custom CRISPR model for IgA binding research.
Frequently Asked Questions About IgA binding
What is GO:0019862 IgA binding?
GO:0019862 is a Gene Ontology molecular function term defined as binding to an immunoglobulin of the IgA isotype, encompassing interactions with IgA1, IgA2, and their monomeric, dimeric, and secretory forms.
What genes are involved in IgA binding?
Key genes include FCAR (CD89), PIGR, FCAMR, JCHAIN, IGHA1, IGHA2, and glycosylation enzymes such as C1GALT1 and C1GALT1C1.
Which receptor is the main IgA receptor on immune cells?
FcαRI (CD89), encoded by FCAR, is the principal IgA Fc receptor on myeloid cells and mediates phagocytosis and inflammatory signaling.
How does IgA binding contribute to IgA nephropathy?
Decreased IgA binding levels and altered glycosylation, including increased IgG sialylation, have been observed in IgA nephropathy, implicating IgA-receptor interactions in disease pathogenesis.
What is the role of pIgR in IgA binding?
pIgR binds dimeric IgA and transcytoses it across epithelial cells, releasing secretory IgA with the secretory component into mucosal secretions.
Can IgA bind to gut bacteria?
Yes, IgA coats specific microbial strains in the healthy human gut, and this coating can be modulated in inflammatory bowel disease, as shown by metagenomic immunoglobulin sequencing.
What methods are used to study IgA binding?
Common methods include surface plasmon resonance, flow cytometry, IgA-SEQ, mass spectrometry glycomics, ELISA, and transcytosis assays.
How is IgA binding regulated?
IgA binding is regulated by cytokines BAFF and APRIL, glycosylation enzymes such as C1GALT1, receptor expression levels, and microbial IgA-binding proteins.
What diseases are linked to IgA binding?
IgA binding is linked to IgA nephropathy, autoimmune nephropathy, allergic disease, and inflammatory bowel disease.
How can CRISPR help study IgA binding?
CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of IgA receptor genes, glycosylation enzymes, and signaling components in human cells.
Conclusion
GO:0019862 (IgA binding) defines a molecular function that bridges mucosal immunity, microbial ecology, and human disease. The interaction of IgA with receptors such as FcαRI, pIgR, and Fcα/μR governs immune exclusion, transcytosis, and inflammatory signaling, while glycosylation and cytokine networks fine-tune binding specificity and affinity. Dysregulated IgA binding is implicated in IgA nephropathy, allergic disease, and inflammatory bowel disease, making it a compelling target for functional genomics and therapeutic development. CRISPR-based cell models and screening services from EDITGENE provide a rigorous path to dissect these mechanisms and accelerate translation.
References
- 1. Shamji MH et al.. 2021. The role of allergen-specific IgE, IgG and IgA in allergic disease.. Allergy 76(12):3627-3641 PMID: 33999439
- 2. Cai J et al.. 2023. Telitacicept for autoimmune nephropathy.. Front Immunol 14:1169084 PMID: 37342346
- 3. Liu Y et al.. 2024. Decreased IgA binding levels were accompanied by increased IgG sialylation in IgA nephropathy.. Clin Nephrol 102(2):89-96 PMID: 38856027
- 4. Olm MR et al.. 2025. Metagenomic immunoglobulin sequencing reveals IgA coating of microbial strains in the healthy human gut.. Nat Microbiol 10(1):112-125 PMID: 39747692
- 5. Woof JM. 2002. The human IgA-Fc alpha receptor interaction and its blockade by streptococcal IgA-binding proteins.. Biochem Soc Trans 30(4):491-4 PMID: 12196121
- 6. Monteiro RC et al.. 2003. IgA Fc receptors.. Annu Rev Immunol 21:177-204 PMID: 12524384
- 7. Takahashi K et al.. 2024. Mouse IgA modulates human gut microbiota with inflammatory bowel disease patients.. J Gastroenterol 59(9):812-824 PMID: 38874761
- 8. Beyer H et al.. 2024. Functional studies with IgM and IgA immunoglobulins: binding to pIgR, FcαμR, FcμR, and CDC activities.. APMIS 132(4):277-288 PMID: 38232051
